CHARLES S. BULLEN STOMACARE LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023
Company Registration No. 03137450 (England and Wales)
CHARLES S. BULLEN STOMACARE LIMITED
COMPANY INFORMATION
Directors
Mr P F Bullen
Mr P A Bullen
Mr I N Burton
Mr J M Charles
Company number
03137450
Registered office
C/o DSG
Castle Chambers
43 Castle Street
Liverpool
Merseyside
L2 9TL
Auditor
DSG
Castle Chambers
43 Castle Street
Liverpool
L2 9TL
Business address
Glacier Building
Brunswick Business Park
Harrington Road
Liverpool
L3 4BH
CHARLES S. BULLEN STOMACARE LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3
Directors' responsibilities statement
4
Independent auditor's report
5 - 7
Statement of comprehensive income
8
Balance sheet
9
Statement of changes in equity
10
Notes to the financial statements
11 - 20
CHARLES S. BULLEN STOMACARE LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2023
- 1 -
The directors present the strategic report for the year ended 31 March 2023.
Principal activity and fair review of business
The principal activities of the company in the year under review were the sale of stomacare, urology and woundcare equipment.
The results for the year show a pre-tax profit of £6,365,108 (2022: £5,097,009) and sales of £58,899,027 (2022: £53,530,619).
The company has net assets of £15,022,984 (2022: £9,868,350).
The year to 31 March 2023 has seen continued stability in the margins achieved in the business in what can be a competitive marketplace. There has been a focus on cash management during the year and this has seen significant benefits in the levels of headroom available in the business to allow strategic decisions to be taken and to reduce the level of interest payable. This is expected to continue in the future.
The business continues to invest significantly in fixed assets including IT systems to ensure that the Group continues to offer a cutting edge service to its patients and other stakeholders.
The business increased it's level of stock holding at the year end in the approach to keeping up with rising customer demand. Consequently, stock levels increased to £4,014,061 (2022: £3,649,618). The increased level of stockholding has been maintained since year end and is unlikely to change in the near future.
Principal risks and uncertainties
Business risk
The management of the business is subject to certain risks. These include the risk of competition, loss of key personnel and the risk of losing the Dispensing Appliance Contractor (DAC) Licences which are held by other group entities. Management deal with risks in a proactive manner to minimise any loss of trade to the company.
Economic risk
The key business risks and uncertainties affecting the company are considered to relate to the economy in general and the pharmaceutical industry in particular. Other factors include competition from both national and independent pharmaceutical distributors, employee retention and product availability.
Credit risk
Credit risk is a constant risk and all new customers are reviewed and their financial position assessed before acceptance. The debt from existing customers is monitored on a regular basis to reduce the cash flow risk.
Key performance indicators
It is envisaged that when assessing the performance of the business against key performance indicators such as turnover, gross profit, cost control and overall profitability, the company will continue to perform well and develop in line with its business plan.
CHARLES S. BULLEN STOMACARE LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
- 2 -
Future developments
The directors have considered the future activities of the company and consider that they are well placed to manage their business risks and take advantage of any business opportunities that arise.
Promoting the success of the company
The Board of Directors, in line with their duties under s172 of the Companies Act 2006, act in a way they consider, in good faith, would be most likely to promote the success of the Company for the benefit of its members as a whole, and in doing so have regard to a range of matters when making decisions for the long term. Key decisions and matters that are of strategic importance to the Company are appropriately informed by s172 factors.
Details of the Company's key stakeholders and how we engage with them are set out below.
Shareholders
Maximising the long-term value for our shareholders is very important.
Colleagues
Our people are crucial to our success as a company and, with that in mind, we have continued to engage closely with them and invest in appropriate training and development. We ensure that all appropriate policies and procedures are in place to promote employee wellbeing and that employees have access to support where needed, be that via health schemes or confidential whistleblowing lines.
Customers
We strive to ensure that our customers receive class-leading service across the company, built on our long-standing and deeply embedded relationships. The Company is committed to maintaining good long-term relationships with customers.
Suppliers
We engage closely with our suppliers to ensure that our relationships are mutually beneficial and long lasting. We onboard suppliers in a controlled manner.
Communities
We aim to work closely with the communities in which we operate and have ensured that where possible we support charitable work carried out by our employees. We also ensure that all staff are aware of the Modern Slavery Act 2015 policy and statement.
Government and regulators
A key area of focus for the business is ensuring compliance with all applicable laws and regulations.
The board is kept fully abreast of any legal and regulatory developments as and when they arise.
Going forward the directors will continue the strong compliance culture in the business, adhering to the robust corporate governance policies.
Mr P A Bullen
Director
22 December 2023
CHARLES S. BULLEN STOMACARE LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 MARCH 2023
- 3 -
The directors present their annual report and financial statements for the year ended 31 March 2023.
Results and dividends
The results for the year are set out on page 8.
No ordinary dividends were paid. The directors do not recommend payment of a final dividend.
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
Mr P F Bullen
Mr P A Bullen
Mr I N Burton
Mr J M Charles
Qualifying third party indemnity provisions
The company has made qualifying third party indemnity provisions for the benefit of its directors during the year. These provisions remain in force at the reporting date.
Post reporting date events
Post year end a dividend of £6.7 Million was issued and paid up the the group to enable a share buy back in Trevally Holdings Limited.
Auditor
The auditor, DSG, is deemed to be reappointed under section 487(2) of the Companies Act 2006.
Energy and carbon report
The company is a subsidiary undertaking and included within the consolidated accounts of Trevally Holdings Limited at 31 March 2023 which include the required disclosures on energy consumption.
Strategic report
The company has chosen in accordance with Companies Act 2006, s. 414C(11) to set out in the company's strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.
On behalf of the board
Mr P A Bullen
Director
22 December 2023
CHARLES S. BULLEN STOMACARE LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 MARCH 2023
- 4 -
The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
CHARLES S. BULLEN STOMACARE LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF CHARLES S. BULLEN STOMACARE LIMITED
- 5 -
Opinion
We have audited the financial statements of Charles S. Bullen Stomacare Limited (the 'company') for the year ended 31 March 2023 which comprise the statement of comprehensive income, the balance sheet, the statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 31 March 2023 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
CHARLES S. BULLEN STOMACARE LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF CHARLES S. BULLEN STOMACARE LIMITED
- 6 -
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.
Discussions with and enquiries of management and those charged with governance were held with a view to identifying those laws and regulations that could be expected to have a material impact on the financial statements. During the engagement team briefing, the outcomes of these discussions and enquiries were shared with the team, as well as consideration as to where and how fraud may occur in the entity. The following laws and regulations were identified as being of significance to the entity:
Those laws and regulations considered to have a direct effect on the financial statements include UK financial reporting standards, Company Law, Tax and Pensions legislation, and distributable profits legislation.
Those laws and regulations for which non-compliance may be fundamental to the operating aspects of the business and therefore may have a material effect on the financial statements include environmental regulations, health and safety legislation, trades description act, employment legislation and pharmaceutical regulations in accordance with the health and social care act 2012.
Audit procedures undertaken in response to the potential risks relating to irregularities (which include fraud and non-compliance with laws and regulations) comprised of: inquiries of management and those charged with governance as to whether the entity complies with such laws and regulations; enquiries with the same concerning any actual or potential litigation or claims; inspection of relevant legal correspondence; review of board minutes; testing the appropriateness of journal entries; reviewing post year end payments for evidence of claims pay outs and the performance of analytical review to identify unexpected movements in account balances which may be indicative of fraud.
No instances of material non-compliance were identified. However, the likelihood of detecting irregularities, including fraud, is limited by the inherent difficulty in detecting irregularities, the effectiveness of the entity’s controls, and the nature, timing and extent of the audit procedures performed. Irregularities that result from fraud might be inherently more difficult to detect than irregularities that result from error. As explained above, there is an unavoidable risk that material misstatements may not be detected, even though the audit has been planned and performed in accordance with ISAs (UK).
CHARLES S. BULLEN STOMACARE LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF CHARLES S. BULLEN STOMACARE LIMITED
- 7 -
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.
Jean Ellis BA FCA CTA
Senior Statutory Auditor
For and on behalf of DSG
22 December 2023
Chartered Accountants
Statutory Auditor
Castle Chambers
43 Castle Street
Liverpool
L2 9TL
CHARLES S. BULLEN STOMACARE LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2023
- 8 -
2023
2022
Notes
£
£
Turnover
2
58,899,027
53,530,619
Cost of sales
(41,133,390)
(37,849,003)
Gross profit
17,765,637
15,681,616
Distribution costs
(1,272,173)
(1,104,066)
Administrative expenses
(10,112,483)
(9,479,894)
Operating profit
3
6,380,981
5,097,656
Interest receivable and similar income
5
134
Interest payable and similar expenses
6
(16,007)
(647)
Profit before taxation
6,365,108
5,097,009
Tax on profit
7
(1,210,474)
(966,544)
Profit for the financial year
5,154,634
4,130,465
The notes on pages 11 to 20 form part of these financial statements.
CHARLES S. BULLEN STOMACARE LIMITED
BALANCE SHEET
AS AT 31 MARCH 2023
31 March 2023
- 9 -
2023
2022
Notes
£
£
£
£
Current assets
Stocks
9
4,014,061
3,649,618
Debtors
10
23,714,989
17,899,768
Cash at bank and in hand
331
44,843
27,729,381
21,594,229
Creditors: amounts falling due within one year
11
(12,706,397)
(11,725,879)
Net current assets
15,022,984
9,868,350
Capital and reserves
Called up share capital
14
2
2
Profit and loss reserves
15,022,982
9,868,348
Total equity
15,022,984
9,868,350
The financial statements were approved by the board of directors and authorised for issue on 22 December 2023 and are signed on its behalf by:
Mr P A Bullen
Director
Company registration number 03137450 (England and Wales)
CHARLES S. BULLEN STOMACARE LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2023
- 10 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 April 2021
2
5,737,883
5,737,885
Year ended 31 March 2022:
Profit and total comprehensive income
-
4,130,465
4,130,465
Balance at 31 March 2022
2
9,868,348
9,868,350
Year ended 31 March 2023:
Profit and total comprehensive income
-
5,154,634
5,154,634
Balance at 31 March 2023
2
15,022,982
15,022,984
CHARLES S. BULLEN STOMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023
- 11 -
1
Accounting policies
Company information
Charles S. Bullen Stomacare Limited is a private company limited by shares incorporated in England and Wales. The registered office is C/o DSG, Castle Chambers, 43 Castle Street, Liverpool, Merseyside, L2 9TL.
The principal activity of the company is disclosed in the Strategic Report.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:
Section 4 ‘Statement of Financial Position’: Reconciliation of the opening and closing number of shares;
Section 7 ‘Statement of Cash Flows’: Presentation of a statement of cash flow and related notes and disclosures;
Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instrument Issues’: Carrying amounts, interest income/expense and net gains/losses for each category of financial instrument; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income;
Section 26 ‘Share based Payment’: Share-based payment expense charged to profit or loss, reconciliation of opening and closing number and weighted average exercise price of share options, how the fair value of options granted was measured, measurement and carrying amount of liabilities for cash-settled share-based payments, explanation of modifications to arrangements;
Section 33 ‘Related Party Disclosures’: Compensation for key management personnel.
The financial statements of the company are consolidated in the financial statements of The Bullen Healthcare Group Limited. These consolidated financial statements are available from its registered office, c/o Castle Chambers, 43 Castle Street, Liverpool, L2 9TL.
1.2
Going concern
Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Turnover
Turnover represents amounts receivable for goods net of VAT and trade discounts. Revenue is recognised as customers are invoiced; at the point of delivery of goods.
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on despatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
CHARLES S. BULLEN STOMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
1
Accounting policies
(Continued)
- 12 -
1.4
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:
Fixtures, fittings & equipment
25% reducing balance
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.5
Stocks
Stock is valued at the lower of cost and net realisable value. Cost includes all overheads incurred in bringing each product to its present location and condition. Net realisable value is based on estimated selling price.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.6
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.7
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
CHARLES S. BULLEN STOMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
1
Accounting policies
(Continued)
- 13 -
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
CHARLES S. BULLEN STOMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
1
Accounting policies
(Continued)
- 14 -
Other financial liabilities
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.
Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently being measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value though profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Derecognition of financial liabilities
Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.
1.8
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.9
Derivatives
Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.
A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.
1.10
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
CHARLES S. BULLEN STOMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
1
Accounting policies
(Continued)
- 15 -
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.11
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.12
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.13
Leases
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
1.14
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
2
Turnover and other revenue
An analysis of the company's turnover is as follows:
2023
2022
£
£
Turnover analysed by class of business
Sale of goods
58,899,027
53,530,619
CHARLES S. BULLEN STOMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
2
Turnover and other revenue
(Continued)
- 16 -
2023
2022
£
£
Turnover analysed by geographical market
United Kingdom
58,899,027
53,530,619
2023
2022
£
£
Other revenue
Interest income
134
-
3
Operating profit
2023
2022
Operating profit for the year is stated after charging:
£
£
Exchange losses
142
2
Operating lease charges
391,219
405,257
4
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2023
2022
Number
Number
Selling and manufacturing
34
25
Stores
42
35
Administration
79
70
Total
155
130
Their aggregate remuneration comprised:
2023
2022
£
£
Wages and salaries
4,153,145
3,523,835
Social security costs
331,028
254,274
Pension costs
92,037
75,082
4,576,210
3,853,191
CHARLES S. BULLEN STOMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
- 17 -
5
Interest receivable and similar income
2023
2022
£
£
Interest income
Other interest income
134
6
Interest payable and similar expenses
2023
2022
£
£
Other finance costs:
Other interest
16,007
647
7
Taxation
2023
2022
£
£
Current tax
UK corporation tax on profits for the current period
1,210,474
969,119
Adjustments in respect of prior periods
(2,575)
Total current tax
1,210,474
966,544
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2023
2022
£
£
Profit before taxation
6,365,108
5,097,009
Expected tax charge based on the standard rate of corporation tax in the UK of 19.00% (2022: 19.00%)
1,209,371
968,432
Tax effect of expenses that are not deductible in determining taxable profit
1,103
687
Under/(over) provided in prior years
(2,575)
Taxation charge for the year
1,210,474
966,544
CHARLES S. BULLEN STOMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
- 18 -
8
Tangible fixed assets
Fixtures, fittings & equipment
£
Cost
At 1 April 2022 and 31 March 2023
16,739
Depreciation and impairment
At 1 April 2022 and 31 March 2023
16,739
Carrying amount
At 31 March 2023
At 31 March 2022
9
Stocks
2023
2022
£
£
Finished goods and goods for resale
4,014,061
3,649,618
Stock is stated after provisions for impairment of £308,598 (2022: £347,516).
10
Debtors
2023
2022
Amounts falling due within one year:
£
£
Trade debtors
14,604,041
12,984,232
Corporation tax recoverable
14,874
2,059
Amounts owed by group undertakings
3,500,000
3,500,000
Other debtors
5,574,957
1,389,153
Prepayments and accrued income
21,117
24,324
23,714,989
17,899,768
CHARLES S. BULLEN STOMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
- 19 -
11
Creditors: amounts falling due within one year
2023
2022
Notes
£
£
Bank loans
12
68,541
Trade creditors
6,758,182
6,064,166
Amounts owed to group undertakings
3,197,137
3,138,070
Corporation tax
710,474
969,119
Other taxation and social security
583,744
582,298
Other creditors
609,277
35,190
Accruals and deferred income
779,042
937,036
12,706,397
11,725,879
12
Loans and overdrafts
2023
2022
£
£
Bank overdrafts
68,541
Payable within one year
68,541
The Bank overdraft is secured by fixed and floating charges over all the assets of the company.
13
Retirement benefit schemes
2023
2022
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
92,037
75,082
The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.
14
Share capital
2023
2022
2023
2022
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
2
2
2
2
CHARLES S. BULLEN STOMACARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
- 20 -
15
Operating lease commitments
Lessee
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:
2023
2022
£
£
Within one year
120,154
141,092
Between two and five years
147,478
156,296
267,632
297,388
16
Related party transactions
Transactions with related parties
Charles S Bullen Executive Pension scheme is a related party due to common directors and trustees.
Bullen Lewis and Partners Limited is a related party due to a common director.
During the year the company entered into the following transactions with related parties:
Rental of DAC licence
Rental of property
2023
2022
2023
2022
£
£
£
£
Other related parties
-
23,200
-
134,000
The following amounts were outstanding at the reporting end date:
2022
2022
2022
Balance
Provision
Net
Amounts due in previous period
£
£
£
Other related parties
168,987
78,364
90,623
Other information
The company has given a joint and several guarantee and a fixed and floating charge to secure its own debt and the debt of other companies in the group to the group's bankers.
17
Ultimate controlling party
The ultimate parent company is Trevally Holdings Limited, a company incorporated in Great Britain and registered in England and Wales. The registered office c/o DSG, Castle Chambers, 43 Castle Street, Liverpool, L2 9TL.
The smallest and largest group into which the results of this entity are consolidated is that headed by The Bullen Healthcare Group Limited.
The ultimate controlling party is Peter Bullen.
2023-03-312022-04-01falseCCH SoftwareCCH Accounts Production 2023.300No description of principal activityMr P F BullenMr P A BullenMr I N BurtonMr J M Charlesfalse031374502022-04-012023-03-3103137450bus:Director12022-04-012023-03-3103137450bus:Director22022-04-012023-03-3103137450bus:Director32022-04-012023-03-3103137450bus:Director42022-04-012023-03-3103137450bus:RegisteredOffice2022-04-012023-03-31031374502023-03-31031374502021-04-012022-03-3103137450core:RetainedEarningsAccumulatedLosses2021-04-012022-03-3103137450core:RetainedEarningsAccumulatedLosses2022-04-012023-03-31031374502022-03-3103137450core:CurrentFinancialInstrumentscore:WithinOneYear2023-03-3103137450core:CurrentFinancialInstrumentscore:WithinOneYear2022-03-3103137450core:CurrentFinancialInstruments2023-03-3103137450core:CurrentFinancialInstruments2022-03-3103137450core:ShareCapital2023-03-3103137450core:ShareCapital2022-03-3103137450core:RetainedEarningsAccumulatedLosses2023-03-3103137450core:RetainedEarningsAccumulatedLosses2022-03-3103137450core:ShareCapital2021-03-3103137450core:RetainedEarningsAccumulatedLosses2021-03-3103137450core:FurnitureFittings2022-04-012023-03-310313745012022-04-012023-03-310313745012021-04-012022-03-3103137450core:UKTax2022-04-012023-03-3103137450core:UKTax2021-04-012022-03-3103137450core:FurnitureFittings2022-03-3103137450core:FurnitureFittings2023-03-3103137450core:FurnitureFittings2022-03-3103137450core:WithinOneYear2023-03-3103137450core:WithinOneYear2022-03-3103137450core:BetweenTwoFiveYears2023-03-3103137450core:BetweenTwoFiveYears2022-03-3103137450bus:PrivateLimitedCompanyLtd2022-04-012023-03-3103137450bus:FRS1022022-04-012023-03-3103137450bus:Audited2022-04-012023-03-3103137450bus:FullAccounts2022-04-012023-03-31xbrli:purexbrli:sharesiso4217:GBP